Skip to content

Services
Choose the pressure point closest to the decision your team needs to make.
Submission & CMCPathway, dossier, evidence, control strategy, or Module 3 readiness.Quality & Data IntegrityGMP remediation, audit trails, completeness, governance, or controls.Inspection & EnforcementReadiness, response, remediation, verification, or sustainment.AI-Enabled CMCStructured CMC data, regulatory modernization, digital governance, and decision support.
Explore all services Start with your situation
Who We Help
Insights
Intelligence hubs
Insights HubThe starting point for XGene analysis and intelligence.Regulatory Intelligence CenterSearch governed regulatory findings, guidance, and related evidence.CMC IntelligenceEvidence connected across the product lifecycle.
Analysis & resources
Articles & Case StudiesSenior-authored analysis with applied regulatory context.Regulatory RecordsBrowse the governed primary-source record archive.Resource CenterStructured reference tools and practical resources.
Media & practical answers
PodcastExpert conversations connecting evidence, judgment, and action.VideoVisual briefings that make regulated systems easier to understand.FAQsConcise answers that orient a regulatory, CMC, quality, or inspection question.
Featured AnalysisThe ICH Q11 Three-Part Justification — What FDA and EMA Require for Starting Material Designation and Where Programs Fall ShortXGene analysis · Aug 22, 2026Read Article →
About
- Methodology
Contact
Book a Call
Discuss a Project

Services
Choose the pressure point closest to the decision your team needs to make.
Submission & CMCPathway, dossier, evidence, control strategy, or Module 3 readiness.Quality & Data IntegrityGMP remediation, audit trails, completeness, governance, or controls.Inspection & EnforcementReadiness, response, remediation, verification, or sustainment.AI-Enabled CMCStructured CMC data, regulatory modernization, digital governance, and decision support.
Explore all services Start with your situation
Who We Help
Insights
Intelligence hubs
Insights HubThe starting point for XGene analysis and intelligence.Regulatory Intelligence CenterSearch governed regulatory findings, guidance, and related evidence.CMC IntelligenceEvidence connected across the product lifecycle.
Analysis & resources
Articles & Case StudiesSenior-authored analysis with applied regulatory context.Regulatory RecordsBrowse the governed primary-source record archive.Resource CenterStructured reference tools and practical resources.
Media & practical answers
PodcastExpert conversations connecting evidence, judgment, and action.VideoVisual briefings that make regulated systems easier to understand.FAQsConcise answers that orient a regulatory, CMC, quality, or inspection question.
Featured AnalysisThe ICH Q11 Three-Part Justification — What FDA and EMA Require for Starting Material Designation and Where Programs Fall ShortXGene analysis · Aug 22, 2026Read Article →
About
- Methodology
Contact
Book a Call
Discuss a Project

Regulatory evidence

Primary-source signals organized for decisions.

Browse governed regulatory records and connect source evidence to technical context, XGene analysis, and practical pathways.

Regulatory evidenceDecision

01Source

02Agency

03Context

04Action

Warning Letters

Pharmathen International Warning Letter: Aseptic Processing Failures and the CMC Pattern Every Sterile Products Quality Director Must Recognize XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

FDA 483 Trend Analysis — March-May 2026: What Inspectors Are Finding at Compounding Pharmacy and Outsourcing Facility Aseptic Programs Right Now XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Zydus Pharmaceuticals Class II Recall — Mirabegron Extended-Release Tablets: The Manufacturing Quality Signal Behind the Notice and What It Reveals About Nitrosamine Control Strategy XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Zhejiang Gaorong Cosmetic Co., Ltd. Added to Import Alert 66-40: The CGMP Pattern Behind the Detention and What Every Quality Director Managing Cross-Category Drug, Biologic, and Supplement Supply Chains Must Know XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Consent Decrees

Inside Genzyme’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will Accept XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

FDA Guidance / Regulatory Developments

FDA’s New Container Closure and Device Constituent Part Draft Guidance for Biosimilars — Why the Comparative Task Analysis Framework Deserves a Formal XGene-Style Comment XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

International Enforcement

International GMP Enforcement — Q3 2026: Pattern Analysis Across 14 Actions and What the Trend Signals for Global Pharmaceutical Quality XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Warning Letters

Pharmathen International Warning Letter: Aseptic Processing Failures and the CMC Pattern Every Sterile Products Quality Director Must Recognize XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

FDA 483 Trend Analysis — March-May 2026: What Inspectors Are Finding at Compounding Pharmacy and Outsourcing Facility Aseptic Programs Right Now XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Zydus Pharmaceuticals Class II Recall — Mirabegron Extended-Release Tablets: The Manufacturing Quality Signal Behind the Notice and What It Reveals About Nitrosamine Control Strategy XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Zhejiang Gaorong Cosmetic Co., Ltd. Added to Import Alert 66-40: The CGMP Pattern Behind the Detention and What Every Quality Director Managing Cross-Category Drug, Biologic, and Supplement Supply Chains Must Know XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Consent Decrees

Inside Genzyme’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will Accept XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

FDA Guidance / Regulatory Developments

FDA’s New Container Closure and Device Constituent Part Draft Guidance for Biosimilars — Why the Comparative Task Analysis Framework Deserves a Formal XGene-Style Comment XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

International Enforcement

International GMP Enforcement — Q3 2026: Pattern Analysis Across 14 Actions and What the Trend Signals for Global Pharmaceutical Quality XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Public library

Browse the published XGene collection.

Insights Hub →

Regulatory Record Cascade Specialty Pharmacy FDA 483: 6 Observations at Poulsbo, Washington and the Quality Management System Pattern Every Compounding Pharmacy Should Assess FDA investigators Lillian S. Wu and Youkeun Kim, working out of the Seattle District Office, closed a ten-day inspection of Cascade Specialty Pharmacy, LLC in Poulsbo, Washington on… Aug 22, 2026 →

Regulatory Record Turbare Manufacturing FDA 483: 4 Observations at Conway, Arkansas and the Aseptic/Sterile Manufacturing Pattern Every 503B Outsourcing Facility Should Assess FDA investigator Sangeeta M. Khurana of the Dallas District Office closed an eleven-day inspection of Turbare Manufacturing's 503B outsourcing facility in Conway, Arkansas on May 7, 2026, documenting… Aug 22, 2026 →

Regulatory Record QuVa Pharma, Inc. FDA 483: 3 Observations at Sugar Land, Texas and the Aseptic/Sterile Manufacturing Pattern Every 503B Outsourcing Facility Should Assess FDA investigator Camerson E. Moore of the Dallas District Office closed an eight-day inspection of QuVa Pharma, Inc.'s 503B outsourcing facility in Sugar Land, Texas on May 4,… Aug 22, 2026 →

Regulatory Record BPI Labs, LLC FDA 483: 4 Observations at Largo, Florida and the Aseptic/Sterile Manufacturing Pattern Every 503B Outsourcing Facility Should Assess FDA investigator Lisa R. Hilliard of the Maitland, Florida District Office closed a 10-day inspection of BPI Labs, LLC's 503B outsourcing facility in Largo, Florida on April 17,… Aug 22, 2026 →

Regulatory Record Wells Pharma of Houston LLC FDA 483: 6 Observations at Houston, Texas and the Quality Management System/CAPA Pattern Every 503B Outsourcing Facility Should Assess FDA investigators closed an 11-inspection-day review of Wells Pharma of Houston LLC's 503B outsourcing facility on April 13, 2026, issuing a six-observation Form 483 (Amendment 1, issued April… Aug 22, 2026 →

Regulatory Record FDA’s New Container Closure and Device Constituent Part Draft Guidance for Biosimilars — Why the Comparative Task Analysis Framework Deserves a Formal XGene-Style Comment On August 3, 2026, FDA announced the availability of a draft guidance for industry titled "Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent… Aug 22, 2026 →

Regulatory Record FDA’s CMC Readiness Strategy for Accelerated Clinical Development — Why Breakthrough, Fast Track, and RMAT Programs Need a Documented CDRP Engagement Plan Now On July 23, 2026, FDA published a notice of availability for its Strategy Document on Facilitating Chemistry, Manufacturing, and Controls Readiness for Products With Accelerated Clinical Development (91… Aug 22, 2026 →

Regulatory Record SUPAC Modernization Comment Reopening — Why the Risk-Based Change Classification Framework Every CMC Program Uses Daily Is Now Up for Revision Today, July 13, 2026, is the last day of a reopened public comment window on Docket FDA-2026-N-0809, FDA's Request for Information (RFI) on modernizing the Scale-Up and Postapproval… Aug 22, 2026 →

Regulatory Record FDA’s Draft Guidance on Leveraging Prior Knowledge for Genome Editing Gene Therapies — The CMC Precedent-Sharing Framework Every GT Program Should Map Before September 1 On June 2, 2026, FDA's Center for Biologics Evaluation and Research (CBER) posted a new draft guidance, "Leveraging Prior Knowledge in the Development of Human Gene Therapy Products… Aug 22, 2026 →

Regulatory Record XCAF-NOV-029 — Regulatory Intelligence Sunny Pharmtech, Inc. Recall — Cyclophosphamide for Injection: The Sterile Manufacturing System Failure Behind a Steel-Particulate Recall and What Every Aseptic Fill-Finish Director Must Verify Now Aug 22, 2026 →

Regulatory Record six SKUs of isopropyl alcohol 70% antiseptic solution across two brand identities — its own Gasco-branded line and a pri — Regulatory Intelligence Gasco Industrial Corp., a Gurabo, Puerto Rico manufacturer, has recalled six SKUs of isopropyl alcohol 70% antiseptic solution across two brand identities — its own Gasco-branded line and… Aug 22, 2026 →

Regulatory Record Revitaderm Wound Care Gel (benzalkonium chloride 0 — Regulatory Intelligence Blaine Labs Inc, a Santa Fe Springs, California manufacturer, has recalled Revitaderm Wound Care Gel (benzalkonium chloride 0.1%, 1.0 fl. oz. bottles) under a Class I classification confirmed… Aug 22, 2026 →

Previous 1 2 3 4 5 Next

XGene Intelligence Discovery

Search this collection and connected XGene intelligence.

Stay within this content family or broaden into related evidence, analysis, resources, and services.

Search Content Domain CMC Authority Action Modality Region Sort

Loading governed XGene intelligence…

Regulatory and quality consulting for pharmaceutical, biotechnology, and medical-device organizations.

Services

Regulatory Strategy CMC & Module 3 Quality & Data Integrity Inspection Readiness AI-Enabled CMC

Insights

Insights Hub Regulatory Intelligence Center Articles & Case Studies CMC Intelligence Resource Center Podcast Video

Company

About XGene Who We Help Contact Book a Call Discuss a Project

© 2026 XGene LLC · XGene Consulting Services · Troy, Michigan Privacy & Cookies · Terms · Disclaimer · Accessibility

XGene Navigator

Find the right evidence, insight, or service.

Search XGene

Services Regulatory Evidence Analysis FAQs Resources Video Podcast

Start typing to search across XGene's public knowledge base.

Saved for later

My XGene Library

Save public XGene articles, records, resources, and services on this device for quick return.

Saved items

Recently viewed